# VeraDermics Raises $472M Post-IPO Equity

> VeraDermics' hair-loss drug IPO soars 567% as company raises $472 million in post-IPO equity.
- Title: VeraDermics Raises $472M Post-IPO Equity · Dealroom | Shortify
- Summary: VeraDermics' hair-loss drug IPO soars 567% as company raises $472 million in post-IPO equity. VeraDermics raised $472 million in post-IPO equity after its…
- Keywords: veradermics, hair-loss drug, ipo, post-ipo equity, phl, minoxidil, clinical-stage biotech, startups, business, Raises, 472M, Post-IPO
- Source: Dealroom — https://dealroom.co/news/163451-veradermics-raises-472m-in-post-ipo-equity-after-hair-loss-drug-ipo-soar
- Published: 2026-10-17T13:11:59+00:00
- Read time: 1 min
- Topics: veradermics, hair-loss drug, ipo, post-ipo equity, phl, minoxidil, clinical-stage biotech, startups, business
## What's the deal?
VeraDermics, a clinical-stage biotech developing an oral treatment for pattern hair loss, raised $472 million in a post-IPO equity round announced in May 2026.
## Why now?
The company listed before its Phase 3 clinical trial data landed to build capital and attract investors for a potential public entrance.

> build capital
## By the numbers
Shares doubled on the February 4 debut and were up 567% as of October 14, the highest percentage return of any 2026 IPO.

> 567%
## The endgame
VeraDermics has one drug candidate, VDPHL01, an oral, non-hormonal extended-release formulation of minoxidil for both men and women.

> VDPHL01
## Key takeaway

VeraDermics raised $472 million in post-IPO equity after its hair-loss drug IPO surged 567% in 2026.